Press "Enter" to skip to content

Patent delisted for Incyte Corp drug JAKAFI

0
Copyright © DrugPatentWatch. Originally published at Patent delisted for Incyte Corp drug JAKAFI

Annual Drug Patent Expirations for JAKAFI
Jakafi is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug and one Paragraph IV challenge.

Drug patent litigation for JAKAFI.

This drug has one hundred and forty-nine patent family members in forty-one countries.

The generic ingredient in JAKAFI is ruxolitinib phosphate. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at Patent delisted for Incyte Corp drug JAKAFI
Do NOT follow this link or you will be banned from the site!